Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer

被引：0
|
作者：
Muriel Lainé
Sean W. Fanning
Ya-Fang Chang
Bradley Green
Marianne E. Greene
Barry Komm
Justyna D. Kurleto
Linda Phung
Geoffrey L. Greene
机构：
[1] The University of Chicago,The Ben May Department for Cancer Research
[2] Loyola University Chicago,Department of Cancer Biology
[3] Komm-Sandin Pharma Consulting,undefined
来源：
Breast Cancer Research | / 23卷
关键词：
Breast cancer; Endocrine resistant; Fulvestrant; Lasofoxifene; Selective estrogen receptor modulator;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer
    Laine, Muriel
    Fanning, Sean W.
    Chang, Ya-Fang
    Green, Bradley
    Greene, Marianne E.
    Komm, Barry
    Kurleto, Justyna D.
    Phung, Linda
    Greene, Geoffrey L.
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [2] Lasofoxifene alone or in combination with palbociclib as an effective treatment for therapy-resistant ER-positive metastatic breast cancer
    Laine, Muriel
    Kurleto, Justyna D.
    Greene, Marianne E.
    Phung, Linda
    Komm, Barry S.
    Greene, Geoffrey L.
    CANCER RESEARCH, 2020, 80 (16)
  • [3] Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer
    Laine, Muriel
    Greene, Marianne E.
    Kurleto, Justyna D.
    Bozek, Grazyna
    Leng, Tiffany
    Huggins, Rosemary J.
    Komm, Barry S.
    Greene, Geoffrey L.
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [4] Lasofoxifene as a potential treatment for aromatase inhibitor resistant ER positive breast cancer
    Laine, Muriel
    Greene, Marianne E.
    Leng, Tiffany
    Kurleto, Justyna D.
    Li, Sophia
    Komm, Barry
    Greene, Geoffrey L.
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Lasofoxifene as a potential treatment for ER plus metastatic breast cancer.
    Laine, Muriel
    Fanning, Sean William
    Greene, Marianne
    Chang, Ya-fang
    Phung, Linda
    Tan, Tina T.
    Hiipakka, Richard
    Komm, Barry
    Greene, Geoffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] A novel role for ESRP1 in regulating proliferation in therapy-resistant ER-positive breast cancer
    Gokmen-Polar, Yesim
    Gu, Yuan
    Gu, Xiaoping
    Badve, Sunil S.
    CANCER RESEARCH, 2019, 79 (13)
  • [7] Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer
    Li-Tong Yao
    Mo-Zhi Wang
    Meng-Shen Wang
    Xue-Ting Yu
    Jing-Yi Guo
    Tie Sun
    Xin-Yan Li
    Ying-Ying Xu
    World Journal of Clinical Cases, 2019, (15) : 1937 - 1953
  • [8] Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer
    Yao, Li-Tong
    Wang, Mo-Zhi
    Wang, Meng-Shen
    Yu, Xue-Ting
    Guo, Jing-Yi
    Sun, Tie
    Li, Xin-Yan
    Xu, Ying-Ying
    WORLD JOURNAL OF CLINICAL CASES, 2019, 7 (15) : 1937 - 1953
  • [9] The retrospective cohort study of hormonal therapy resistant ER-positive breast cancer
    Fujisawa, Tomomi
    Morishita, Akiko
    Miyamoto, Takeshi
    Yanagita, Yasuhiro
    ANNALS OF ONCOLOGY, 2015, 26 : 142 - 142
  • [10] What is the best therapy for ER-positive breast cancer?
    不详
    EJC SUPPLEMENTS, 2004, 2 (09): : 62 - 64
12345